Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Exclusion Criteria

• •Participation in ongoing or previous denosumab clinical trials
• •Currently enrolled in another investigational device or drug study, or less than 6 months since ending another investigational device or drug study(s), or receiving other investigational agent(s)
• •Contra-indicated for treatment with Prolia® according to the approved applicable local product label (US/Canada)
• •Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.